Table 4. Fold-difference of gene expression for pairs of adipose depots.

Secondary gene expression analysis was performed with IPA (Ingenuity Systems) software, after logarithmic (log₂) conversion of the data. Relative gene expression for each of the indicated pairswas ranked by the fold-increase or decrease. The “+” sign represents higher expression with reference to the tissue in the denominator, and the “−” sign represents lower expression.

SAT/EAT	VAT/EAT	SAT/VAT
Fold increase
SELE (+4.935); IL6 (+4.734); AREG/ARGEB (+4.502); TREM1 (+4.159); TNFAIP6 (+3.586); EGFL6 (+3.573); AQP9 (+3.443); S100A12 (+3.356); IL8 (+3.304); MMP19 (+3.282)	ITLN1 (+4.944); CLDN1 (+4.544); IL6 (+4.266); BTG3 (+4.100); FLRT3 (+3.845); AREG/AREGB (+3.715); TREM1 (+3.550); DSC3 (+3.481); BCHE (+3.415); UPK1B (+3.350)	EGFL6 (+2.863); NRCAM (+2.081); SELE (+1.857); DMRT3 (+1.717); CLIC6 (+1.637); HMOX1 (+1.591); TNFAIP6 (+1.581); PNP (+1.552); TNC (+1.520); STMN2 (+1.478);
Fold decrease
SPTBN1 (−1.388); MEIS1 (− 1.407); ZNF33B (−1.418); PTGDS (−1.435); PCSK6 (− 1.478); PLAT (−1.483); WT1- AS (−1.589); MYOC (−1.763); C7 (−2.278); GREM1 (−2.595)	HIST1HA4 (−0.640); EMX2 (− 0.652); MYOC (−0.897); CHS1/CSH2 (−1.504)	BNC1 (−3.106); WT1-AS (− 3.267); UPK1B (−3.323); DSC3 (−3.437); GREM1 (− 3.577) BCHE (−3.697); FLRT3 (−3.952); CLDN1 (− 4.922); BTG3 (−5.014); ITLN1 (−5.473)